LXJ-02 is a potent inhibitor of EDPs/EBP peptide–protein interaction, with the K D of 117 μM for EDPs. LXJ-02 activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin.
Products | Products > Peptides | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MMP
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.